Logo

Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP)

Share this

Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP)

Shots:

  • The P-III ENVISION study involves assessing of Givosiran vs PBO in 94 patients with AHP including patients with acute intermittent porphyria (AIP) across 18 countries in ratio 1:1             
  • The ENVISION study resulted in meeting 1EPs & 2EPs i.e- reduction in porphyria attacks- presented at EASL on 13 Apr-2019 with its expected NDA & MAA filing in H2’19
  • Givosiran (SC- 2.5mg/kg/mo) is a RNAi therapeutics- based on Alnylam’s Enhanced Stabilization Chemistry ESC-GalNAc conjugate technology. It has received FDA’s BT & EMA’s PRIME designation and ODD in both- the US & EU

Ref: Alnylam | Image: FDA Headlines

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions